Man Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-620,699
| Closed | -$81.9M | – | 2461 |
|
|
2025
Q1 | $81.9M | Buy |
620,699
+572,102
| +1,177% | +$71.3M | 0.21% | 95 |
|
|
2024
Q4 | $4.06M | Buy |
48,597
+21,098
| +77% | +$1.73M | 0.01% | 1090 |
|
|
2024
Q3 | $2.01M | Sell |
27,499
-33,502
| -55% | -$2.52M | 0.01% | 1304 |
|
|
2024
Q2 | $4.18M | Buy |
61,001
+54,871
| +895% | +$3.81M | 0.01% | 1082 |
|
|
2024
Q1 | $424K | Buy |
6,130
+3,021
| +97% | +$208K | ﹤0.01% | 1837 |
|
|
2023
Q4 | $223K | Buy |
+3,109
| New | +$179K | ﹤0.01% | 1896 |
|
|
2023
Q3 | – | Sell |
-229,536
| Closed | -$13.4M | – | 1737 |
|
|
2023
Q2 | $14.5M | Buy |
+229,536
| New | +$14.3M | 0.04% | 492 |
|
|
2021
Q2 | – | Sell |
-10,179
| Closed | -$345K | – | 2117 |
|
|
2021
Q1 | $345K | Buy |
+10,179
| New | +$353K | ﹤0.01% | 1593 |
|
|
2020
Q2 | – | Sell |
-26,000
| Closed | -$400K | – | 1851 |
|
|
2020
Q1 | $400K | Buy |
+26,000
| New | +$565K | ﹤0.01% | 1328 |
|
|
2019
Q3 | – | Sell |
-196,803
| Closed | -$2.56M | – | 1940 |
|
|
2019
Q2 | $2.56M | Sell |
196,803
-46,200
| -19% | -$593K | 0.01% | 1222 |
|
|
2019
Q1 | $2.96M | Buy |
243,003
+43,200
| +22% | +$552K | 0.01% | 1175 |
|
|
2018
Q4 | $2.28M | Sell |
199,803
-102,545
| -34% | -$1.66M | 0.01% | 1158 |
|
|
2018
Q3 | $6.56M | Sell |
302,348
-26,700
| -8% | -$558K | 0.02% | 844 |
|
|
2018
Q2 | $5.81M | Buy |
329,048
+112,289
| +52% | +$2.28M | 0.02% | 865 |
|
|
2018
Q1 | $4.56M | Buy |
+216,759
| New | +$4.22M | 0.02% | 900 |
|
Other funds holding ITCI
Man Group's ITCI Position: Q2 2025 in Review
Man Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 620,699 shares — an estimated $81.9M sold.
Man Group first reported a position in ITCI in Q1 2018 and held it in 15 quarters. The position peaked at $81.9M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Man Group reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Man Group sold 620,699 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $81.9M.
- Man Group first reported a position in Intra-Cellular Therapies Inc. in Q1 2018 and held it in 15 quarters.
- Man Group's Intra-Cellular Therapies Inc. position peaked at $81.9M in Q1 2025.
- 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Man Group's 13F filing for Q2 2025, filed 14 Aug 2025.